<DOC>
	<DOCNO>NCT00130754</DOCNO>
	<brief_summary>Allogeneic stem cell transplantation treatment choice grow number malignant non-malignant indication . Until recently , myeloablative conjunction immunosuppressive conditioning consider mandatory elimination malignant hematopoietic cell prevent graft rejection . The aim allogeneic non-myeloablative stem cell transplantation ( NST ) induce host-to-graft tolerance fast durable engraftment donor stem cell , mean conditioning , well-tolerated patient . The rationale behind NST strategy induce optimal graft-versus-leukemia ( GVL ) effect elimination malignant cell alloreactive immunocompetent cell match donor alternative standard high-dose myeloablative chemo radiotherapy . The NST protocol therefore mainly base immunosuppression thus contain fludarabine , low dose busulfan anti-T-lymphocyte globulin ( ATG ) . Thymoglobuline polyclonal rabbit antiserum specific human T cell use organ transplantation induction tolerance rejection prevention treatment . It also use stem-cell transplantation ( SCT ) purpose ( e.g . generation tolerance rejection preclusion ) well treatment graft-versus-host disease ( GVHD ) . Data myeloablative protocol suggest ATG SCT significantly reduce risk grade III-IV acute GVHD . This translate reduction transplant-related mortality ( TRM ) increase risk infection thus survival unchanged . Extensive chronic GVHD also significantly show reduced patient receive ATG myeloablative setting . However , role ATG NST protocol never evaluate prospective randomize trial . In view preliminary data suggest additive effect ATG circumstance , investigator Hadassah Medical Organization , evaluate effect ATG NST prospective randomize trial .</brief_summary>
	<brief_title>Thymoglobuline Non-myeloablative Allogeneic Stem-cell Transplantation</brief_title>
	<detailed_description>Allogeneic stem cell transplantation ( SCT ) fully match donor treatment choice grow number malignant non-malignant indication . Until recently , myeloablative conjunction immunosuppressive conditioning consider mandatory elimination malignant hematopoietic cell prevent graft rejection . The aim allogeneic non-myeloablative stem cell transplantation ( NST ) induce host-to-graft tolerance fast durable engraftment donor stem cell , mean conditioning , well-tolerated patient . The rationale behind NST strategy induce optimal graft-versus-leukemia ( GVL ) effect elimination malignant cell alloreactive immunocompetent cell match donor alternative standard high-dose myeloablative chemo radiotherapy . The NST protocol therefore mainly base immunosuppression thus contain fludarabine , low dose busulfan anti-T-lymphocyte globulin ( ATG ) . Thymoglobuline polyclonal rabbit antiserum specific human T cell use organ transplantation induction tolerance rejection prevention treatment . It also use SCT purpose ( e.g . generation tolerance rejection preclusion ) well treatment GVHD . Data myeloablative protocol suggest ATG SCT significantly reduce risk grade III-IV acute GVHD . This translate reduction TRM increase risk infection thus survival unchanged . Extensive chronic GVHD also significantly show reduced patient receive ATG myeloablative setting . However , role ATG NST protocol never evaluate prospective randomize trial . In view preliminary data suggest additive effect ATG circumstance propose follow clinical trial . Objectives : To evaluate effect ATG vs. ATG incidence GVHD patient undergo NST . Study parameter : Primary end point - - Acute GVHD occurrence . - Acute GVHD grading . Secondary end point - - Time acute GVHD . - Chronic GVHD occurrence . - Chronic GVHD grading . - Engraftment/graft rejection - Overall survival . - Disease free survival . - Infections . - Transplant-related mortality ( TRM ) . - Transplant-related toxicity ( TRT ) . Treatment schedule : 30 patient fully match donor include . Patients randomize two group : - Patients get rabbit anti-human T lymphocyte globulin ( thymoglobuline R , SangStat ) part pre-transplant conditioning . - Patients get rabbit anti-human T lymphocyte globulin ( thymoglobuline R , SangStat ) part pre-transplant conditioning . Randomization : Randomization do GENZYME Israel Ltd . The center send randomization form GENZYME Israel fax company fax back randomization status patient . Randomization preform day -10 pre-transplant . Inclusion criterion : - Patients age 18-75 year old disease necessitate allogeneic SCT . - Patients must HLA compatible donor willing capable donate peripheral blood stem cell preferably , bone marrow progenitor cell use conventional technique , lymphocyte indicate ( HLA compatible define 5/6 6/6 match relate [ A , B , DR ] 8/8 molecular [ A , B , C , DR ] match unrelated donor ) . - Both patient donor must sign write informed consent . - Patients must ECOG PS ≤ 2 ; Creatinine &lt; 2.0 mg/dl ; Ejection fraction &gt; 40 % ; DLCO &gt; 50 % predict ; Serum bilirubin &lt; 3 gm/dl ; elevate GPT GOT &gt; 3 x normal value . Exclusion criterion : - Not fulfil inclusion criterion - Active life-threatening infection - Overt untreated infection - Hypersensitivity thymoglobuline rabbit produce immunoglobulin . - HIV seropositivity , hepatitis B C antigen positivity active hepatitis - Pregnant lactating woman . - Donor contraindication ( HIV seropositive confirm Western Blot ; hepatitis B antigenemia ; evidence bone marrow disease ; unable donate bone marrow peripheral blood due concurrent medical condition ) . - Inability comply study requirement . CONDITIONING PROTOCOL : All patient prepare NST protocol ( I.V.fludarabine 30mg/m2/day [ day -10 -5 ] oral busulfan 4mg/kg 4 divide daily dos [ day -6 -5 ] I.V . Busulfex dose 3.2 mg\kg day -6 -5 , without I.V . ATG accord randomization group [ day -4 -1 ] ) . ATG dose schedule : cumulative dose 7.5 mg/kg ATG give follow program - 0.5 mg/kg day -4 , 2.0 mg/kg day -3 , 2.5 mg/kg day -2 , 2.5 mg/kg day -1 . Each day 's infusion time 8 hour . The last dose day -1 give within 24 hour pre stem cell infusion . Prior NST , patient receive trimethoprim/sulfamethoxazole ( 10 mg/kg/d trimethoprim ) day -10 -2 , acyclovir ( 500 mg/m2 x 3/day ) day -6 day +100 , allopurinol ( 300 mg/day ) day -10 -1 . Administration trimethoprim/sulfamethoxazole ( twice weekly ) reinstituted recovery neutropenia preventive measure pneumocystis carinii infection . Starting day -8 , patient monitor pp65 antigenemia/CMV PCR weekly basis detect cytomegalovirus ( CMV ) . Two consecutive positive PCR result one antigenemia one cell positive pp65 serve indication replace acyclovir ganciclovir 10 mg/kg/day minimum two negative test obtain . Neutropenic patient culture-negative fever receive combination gentamicin , cefazolin piperacillin , first line antibiotic protocol . Persisting fever treat amikacin tazocin second line protocol , meropenem vancomycin use third line protocol . In case persistent fever respond antibiotic therapy within 5 day , amphotericin B ( 0.7 mg/kg/d ) add neutropenia resolve . No antifungal prophylaxis give . Graft-vs-host disease ( GVHD ) prophylaxis consist single-drug low-dose , short- term cyclosporine- A ( CSP ) 3 mg/kg i.v . daily two divided dos start day -4 . Once patient mobile CSP administer orally . CSP dosage taper second third month post transplant , accord chimeric status evidence GVHD gradually stop unless patient develop GVHD graft failure . Immediately upon appearance sign symptom GVHD , i.v . methylprednisolone ( 2 mg/kg ) CSP administer . PBSC donor inject subcutaneously granulocyte-colony stimulating factor ( G-Neupogen , 5 mg/kg twice daily 5 day ) mobilize peripheral blood stem cell collect day 5 6 . Definitions : Engraftment : The 1st day PBSC infusion designate `` day 0 '' . Engraftment define ANC &gt; 0.5x10^9/L peripheral WBC &gt; 1x1^09/L 3 consecutive day unsupported platelet &gt; 25x10^9/L . Chimerism : Chimerism assess standard cytogenetic analysis male/female donor-recipient . Residual male cell female chimera detect amelogenine gene method . In sex-matched donor-recipient combination , various number tandem repeat ( VNTR ) polymerase chain reaction ( PCR ) 5 % sensitivity detection use assess presence residual host donor cell . Graft versus host disease ( GVHD ) : Acute chronic GVHD grade accord International Stem Cell Transplantation Registry ( ISCTR ) severity index . Graft rejection : Graft rejection define peripheral blood aplasia marrow hypoplasia &gt; 21 day post-transplant , evidence donor marker reveal cytogenetic molecular technique . Transplant-related mortality ( TRM ) : TRM define mortality occur due transplant procedure , patient complete remission begin condition day +100 . Transplant-related toxicity ( TRT ) : All nonhematological toxicity , include multi-organ dysfunction day 0 +100 , consider regimen-related toxicity grade accord criterion Bearman et al . Time follow-up : study end 1-year post transplant .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Patients age 1875 year old disease necessitate allogeneic SCT . Patients must HLA compatible donor willing capable donate peripheral blood stem cell preferably , bone marrow progenitor cell use conventional technique , lymphocyte indicate ( HLA compatible define 5/6 6/6 match relate [ A , B , DR ] 8/8 molecular [ A , B , C , DR ] match unrelated donor ) . Both patient donor must sign write informed consent . Patients must ECOG performance status ( PS ) ≤ 2 ; Creatinine &lt; 2.0 mg/dl ; Ejection fraction &gt; 40 % ; Diffusing capacity lung carbon monoxide ( DLCO ) &gt; 50 % predict ; Serum bilirubin &lt; 3 gm/dl ; Elevated GPT GOT &gt; 3 x normal value . Not fulfil inclusion criterion Active lifethreatening infection Overt untreated infection Hypersensitivity thymoglobuline rabbit produce immunoglobulin . HIV seropositivity , hepatitis B C antigen positivity active hepatitis Pregnant lactate woman . Donor contraindication ( HIV seropositive confirm Western Blot ; hepatitis B antigenemia ; evidence bone marrow disease ; unable donate bone marrow peripheral blood due concurrent medical condition ) . Inability comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>